Symbols

VNRX

Volitionrx·AMEX

--(--)

VNRX fundamentals

VNRX Q4 2025 Earnings Preview

Volitionrx (VNRX) expects to report earnings on Mar 31, 2026, with estimated revenue of 753.58K (YoY +295.55%), and EPS at -0.0417 (YoY +30.50%).

Revenue estimate / YoY

753.58K

+295.55%

EPS estimate / YoY

-0.0417

+30.50%

Report date

Mar 31, 2026

VNRX Earnings Call Summary for Q4,2025

Revenue Surge: 40% YoY growth to $1.7M, driven by Nu.Q Discover and first human diagnostic sales.
Cost Optimization: 17% expense reduction, positioning for 2026 cost-cutting initiatives.
Breakthroughs: Feline lymphoma test 80% accurate, sepsis study in France, and 95% early-stage cancer detection with Capture-Seq.
Licensing Momentum: 10+ negotiations underway, targeting multi-billion-dollar markets.
Upcoming Milestones: $5M feline cancer milestone, French Nu.Q Cancer reimbursement Q4 2026, and potential liquid biopsy partnerships.

Earnings

EPS

Revenue

Revenue & Expenses

VNRX has released its 2025 Q4 earnings report, with revenue of 447.03K, reflecting a YoY change of 133.25%, and net profit of -6.30M, showing a YoY change of -7.61%. The Sankey diagram below clearly presents VNRX's revenue sources and cost distribution.

Key Indicators

Volitionrx (VNRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Volitionrx (VNRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Volitionrx (VNRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Volitionrx (VNRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown